Skip to main content
null
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Brief Report
    • Cardiovascular Conditions
    • Commentary
    • Correspondence
    • Dermatological Diseases
    • Endocrine Diseases
    • Gastrointestinal Conditions
    • General Indications
    • Genetic Disorders
    • Hematology
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Nephrologic/Hepatologic Conditions
    • Neurological Disorders
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Perspective
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:47514/feed
Cardiovascular Conditions
Vol. 5, Issue 2, 2018January 09, 2018 EDT

Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy

George Ruiz, Jason Yeaw, Cassandra A. Lickert, Ajita P. De, Rolin L. Wade, Janis Pruett, William Drake,
real world evidencetadalafilsildenafilpulmonary arterial hypertensionhealthcare utilization
Copyright Logoccby-4.0 • https://doi.org/10.36469/9812
JHEOR
1.
Ruiz G, Yeaw J, Lickert CA, et al. Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy. JHEOR. 2018;5(2):206-219. doi:10.36469/​9812
Save article as...▾

View more stats

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

Powered by Scholastica, the modern academic journal management system